uniQure (NASDAQ:QURE) Shares Gap Up – Still a Buy?

uniQure N.V. (NASDAQ:QURE)’s share price gapped up before the market opened on Friday . The stock had previously closed at $22.69, but opened at $23.95. uniQure shares last traded at $25.15, with a volume of 914,442 shares traded.

Analyst Ratings Changes

QURE has been the subject of a number of recent research reports. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Chardan Capital reaffirmed a “buy” rating and set a $53.00 target price on shares of uniQure in a research note on Thursday, December 4th. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Stifel Nicolaus dropped their price target on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Finally, Mizuho reduced their price target on shares of uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, December 8th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average target price of $60.82.

uniQure Stock Up 9.6%

The company has a market capitalization of $1.55 billion, a PE ratio of -5.65 and a beta of 0.68. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. The business has a fifty day moving average of $24.22 and a 200 day moving average of $27.94.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. Equities research analysts anticipate that uniQure N.V. will post -3.75 EPS for the current year.

Insider Buying and Selling

In other uniQure news, Director Robert Gut sold 25,613 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares of the company’s stock, valued at $796,260.04. This trade represents a 44.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jack Kaye sold 6,390 shares of uniQure stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 102,247 shares of company stock worth $2,839,298. 4.79% of the stock is owned by company insiders.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC increased its holdings in shares of uniQure by 22.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after acquiring an additional 819,444 shares during the period. Aberdeen Group plc grew its position in uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after purchasing an additional 738,897 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in uniQure in the second quarter valued at $29,217,000. Franklin Resources Inc. raised its holdings in shares of uniQure by 23.9% in the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock valued at $116,073,000 after buying an additional 383,066 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after buying an additional 1,491,486 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.